Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …

Therapeutic radiopharmaceuticals have been researched extensively in the last decade as
a result of the growing research interest in personalized medicine to improve diagnostic …

Abstract Background Dosimetry in [177Lu] Lu-PSMA therapy is a valuable tool to assess
treatment efficacy and toxicity. This study aims to develop a clinically implementable protocol …

In the Last decades, nanotechnology has provided novel and alternative methodologies and
tools in the field of medical oncology, in order to tackle the issues regarding the control and …

Peptide receptor radionuclide therapy (PRRT), over the years, has evolved as an important
modality in the therapeutic armamentarium of advanced, metastatic or inoperable …

Background: The introduction of magnetic resonance (MR)-guided radiation treatment
planning has opened a new space for theranostic nanoparticles to reduce acute toxicity …

Radiometals are increasingly used in nuclear medicine for both diagnostic and therapeutic
purposes. The DOTA ligand (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) …

H3trica is a nonadentate chelating ligand intended for coordinating large radiometal ions,
such as those used in nuclear medicine. This chelator, featuring a triaza-18-crown-6 …

Lutetium-177-labeled radiopharmaceuticals have been used clinically for the treatment of
various malignancies in nuclear medicine. The main characteristics of lutetium-177 (177 Lu) …

The development of clinical imaging techniques significantly improves diagnostic accuracy
and provides guidance for personalized treatment of individuals. However, every single …